Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation (I9DN)

Market Closed
27 Jun, 20:00
2. 69
-0.12
-4.27%
509.83M Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-0.45 Eps
2.81
Previous Close
Day Range
2.69 2.69
Year Range
2.52 4.09
Want to track I9DN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 25 days

Summary

I9DN closed Friday lower at €2.69, a decrease of 4.27% from Thursday's close, completing a monthly decrease of -13.77% or €0.43. Over the past 12 months, I9DN stock lost -13.22%.
I9DN is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
Arbutus Biopharma Corporation has completed 1 stock splits, with the recent split occurring on Nov 04, 2010.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

I9DN Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China

Globenewswire | 1 week ago
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Zacks | 1 month ago
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon

Globenewswire | 1 month ago

Arbutus Biopharma Corporation Dividends

I9DN is not paying dividends to its shareholders.

Arbutus Biopharma Corporation Earnings

31 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
I9DN is not paying dividends to its shareholders.
31 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS

Arbutus Biopharma Corporation (I9DN) FAQ

What is the stock price today?

The current price is €2.69.

On which exchange is it traded?

Arbutus Biopharma Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is I9DN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 509.83M.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Arbutus Biopharma Corporation ever had a stock split?

Arbutus Biopharma Corporation had 1 splits and the recent split was on Nov 04, 2010.

Arbutus Biopharma Corporation Profile

Biotechnology Industry
Healthcare Sector
Lindsay Androski CEO
XBER Exchange
CA03879J1003 ISIN
US Country
44 Employees
- Last Dividend
4 Nov 2010 Last Split
3 Aug 2015 IPO Date

Overview

Arbutus Biopharma Corporation, originally known as Tekmira Pharmaceuticals Corporation until its rebranding in July 2015, is a biopharmaceutical entity involved in the development of innovative treatments for the chronic Hepatitis B virus (HBV) infection primarily within the United States. Headquartered in Warminster, Pennsylvania, Arbutus is dedicated to pioneering new therapeutics that promise a brighter future for individuals battling HBV. Their scientific endeavors extend beyond HBV, venturing into small molecule antiviral medicines aimed at various coronaviruses, including COVID-19, marking their commitment to addressing global viral challenges. Arbutus's strategic alliances with esteemed organizations such as Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc., along with a clinical collaboration with Barinthus Biotherapeutics plc, underscore their prominent role in the biopharmaceutical landscape.

Products and Services

  • Imdusiran (AB-729)
  • A cutting-edge, proprietary RNAi therapeutic that is administered subcutaneously. Imdusiran is targeted at suppressing HBV antigens across the board, including HBsAg, a crucial element in the persistence and replication of the virus in infected individuals. This promising candidate stands at the forefront of Arbutus's HBV pipeline, exemplifying their innovative approach to tackling hepatitis B virus infection.

  • AB-101
  • An oral PD-L1 inhibitor currently under development, AB-101 represents another facet of Arbutus’s therapeutic arsenal against HBV. This novel compound aims to reignite the patient's own HBV-specific immune system, showcasing a unique therapeutic approach by leveraging the body’s inherent defense mechanisms to combat the virus.

  • Small Molecule Antivirals for Coronaviruses
  • In response to the global emergency triggered by the coronavirus pandemic, Arbutus has expanded its research and development to include small molecule antivirals targeting not just HBV but also coronaviruses, including COVID-19. This initiative reflects Arbutus’s flexibility and their commitment to contributing significant solutions to pressing global health crises.

  • Clinical Collaboration with Barinthus Biotherapeutics plc to Evaluate VTP-300
  • The partnership with Barinthus Biotherapeutics plc to assess VTP-300 signifies a strategic collaboration aimed at discovering potent therapeutic options. This-in-progress evaluation underscores the dedication of Arbutus to explore collaborative opportunities that can enhance their product offerings and potentially lead to novel treatment paradigms.

Contact Information

Address: 701 Veterans Circle
Phone: 267 469 0914